Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

ents were randomized 1:1 to receive a total daily dose of 2403 mg pirfenidone, or placebo. CAPACITY 2 enrolled a total of 435 patients, and patients were randomized 2:2:1 to receive a total daily dose of 2403 mg pirfenidone, or placebo, or a total daily dose of 1197 mg pirfenidone, respectively, administered in three divided doses. The lower dose of pirfenidone in CAPACITY 2 provided safety and tolerability data. The pre-specified statistical analysis plan did not call for this low-dose group to be used in any analyses of efficacy. The pooled analyses of the primary and secondary efficacy outcome measures were based on a combined analysis of the 2403 mg group compared with the placebo group across both studies and were considered exploratory.

Enrollment of both trials was completed in less than 13 months following randomization of the first patient into the program in late April 2006. Ninety-seven percent (97%) of all patients in the two CAPACITY studies who were living and had not received a lung transplant, completed their Week 72 study visit.

Each trial in CAPACITY was designed to have greater than 95% statistical power to detect a 50% reduction in the rate of FVC progression compared to placebo after 72 weeks of treatment and greater than 85% statistical power to detect a 40% reduction after the same period, when compared to placebo. The pre-specified secondary endpoints of CAPACITY were:

        1.  Time to worsening of IPF, defined as time to acute IPF
            exacerbation, IPF-related death, lung transplant or respiratory
            hospitalization, whichever comes first
        2.  Progression-free survival defined as time to the first occurrence
            of either of the following (as compared to the patient's
            baseline):
              --  10% absolute decline in percent predicted FVC, or
              --  15% absolute decline in percent predicted Hb-corrected
        
'/>"/>
SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... (PRWEB) May 28, 2015 BioNorth ... serving and representing the life sciences industry in ... of Directors meeting at The Foundry in Dallas ... the organization brought together a broad spectrum of ... underscored the organization's early successes in partnering with ...
(Date:5/28/2015)... -- RXi Pharmaceuticals Corporation (NASDAQ: RXII ), a ... primarily in the areas of dermatology and ophthalmology, today ... million units at a price to the public of ... million. Each unit consists of (i) one share of ... purchase 0.50 of a share of common stock at ...
(Date:5/28/2015)... May 28, 2015  GenVec, Inc. (Nasdaq: GNVC ... Douglas J. Swirsky , will present a company overview ... a.m. EDT on Thursday, June 4, 2015. ... presentation will be available at the following link:  ... GenVec,s website.  To access, visit www.genvec.com , click ...
(Date:5/28/2015)... The Fertility Centers of New England is proud to ... on a new and expanded role as Medical Director. ... oversight and quality assurance for the practice. , “We ... of experienced reproductive endocrinologists,” said Fertility Centers of New ... expertise and compassionate, individualized care have helped set FCNE ...
Breaking Biology Technology:BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3GenVec To Present At The Jefferies Healthcare Conference 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... gene expression studies , require reliable ... purify high quality RNA from a large number of samples. Although the , ... and , clean up, it is ... format. Thus for high-throughput applications, we recommend , ...
... RNA later Tissue , ... the preservation of RNA in intact animal tissues, organs, and ... need to immediately process tissue , samples ... processing. Here we demonstrate that RNA later provides the , ...
... , A. ... RNA amplification , ... utilizes an oligo(dT) primer containing the T7 RNA polymerase , ... at the end of mRNA sequences serves as ...
Cached Biology Technology:RNAi for High Throughput Analysis 2RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis 2RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis 3RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis 4RNA Amplification for Array Analysis 2RNA Amplification for Array Analysis 3RNA Amplification for Array Analysis 4
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... Information with Figures (pdf download) , ... law postulated by Ernst Abbe in 1873 for ... and his co-workers have established a new law ... applications range from the imaging of cell interiors ...
... arrival of the first humans in ancient Australia may ... University of Colorado, Australian National University, and Bates College.* ... researchers traced evidence of diet and the environment contained ... 140,000 years to reconstruct what happened. The remains showed ...
... A team of researchers led by the University of ... becomes permanently etched in the brain - a discovery ... anxiety and post-traumatic stress. , U of T physiology ... of Seoul National University in South Korea, and ...
Cached Biology News:New law for resolution allows unprecedented sharpness in fluorescence microscopy 2New law for resolution allows unprecedented sharpness in fluorescence microscopy 3Did humans cause ecosystem collapse in ancient Australia? 2Study charts origins of fear 2
... active ingredient in Molecular Probes. SlowFadeAntifade ... to act as a free radical ... Our original SlowFade formulation (S-2828) was ... of fluorescein to almost zero (Figure ...
b6-2A12...
... in this kit are prepared with pure ... Biochains Mitochondria Isolation Kit is designed to ... fast and easy way. One kit is ... isolations (enriching mitochondria from 10 20 ...
... is Tecans new Enzyme-Linked Immunosorbent Assay (ELISA) ... EVOlyzer is a dedicated EVO platform for ... washer and incubation units operated by the ... is available in three sizes - 100, ...
Biology Products: